europass

Paolo Calzari

Date of birth: 28/04/1993 | **Nationality:** Italian

WORK EXPERIENCE

MEDICO SPECIALISTA IN ALLERGOLOGIA E IMMUNOLOGIA CLINICA, CONTRATTO IN REGIME DI LIBERA PROFESSIONE C/O AMBULATORIO DI DERMATOLOGIA ALLERGOLOCIA. – S.C. DERMATOLOGIA IRCCS FONDAZIONE CA' GRANDA POLICLINICO DI MILANO – 01/11/2025 – Current – MILANO, ITALY

MEDICO SPECIALISTA IN ALLERGOLOGIA E IMMUNOLOGIA CLINICA – DERMATOS CENTRO DERMATOLOGICO SPECIALISTICO – 01/02/2025 – Current – MILANO, ITALY

MEDICO SPECIALISTA IN ALLERGOLOGIA E IMMUNOLOGIA CLINICA – MED4YOU – 01/07/2025 – Current – ARCORE, ITALY

FREQUENTATORE VOLONTARIO - MEDICO SPECIALISTA IN ALLERGOLOGIA E IMMUNOLOGIA CLINICA – IRCCS FONDAZIONE CA' GRANDA POLICLINICO DI MILANO - S.C. DERMATOLOGIA – 01/02/2024 – 31/10/2025 – MILANO, ITALY

Ambulatorio di dermatologia allergologica nel contesto del quale si eseguono patch test, prick test, visite dermatologiche principalmente inerenti la dermatite atopica e l'orticaria. Durante tali visite si somministrano anche terapie con formaci biologici.

MEDICO SPECIALIZZANDO / MD RESIDENT ALLERGIC DERMATOLOGY SERVICE, OSPEDALE MAGGIORE POLICLINICO DI MILANO (DR.SSA SILVIA FERRUCCI) – UNIVERSITÀ DEGLI STUDI DI MILANO – 01/08/2022 – 26/01/2025 – MILANO, ITALY

Patologie trattate: dermatite atopica, dermatiti da contatto, orticaria cronica spontanea.
Abilità acquisite: gestione di dermatite atopica ed orticaria cronica spontanea, prescrizione di farmaci biologici e small molecules.
Ricerca clinica: gestione di database clinici e produzione scientifica

Treated conditions: atopic dermatitis, contact dermatitis, chronic spontaneous urticaria.
Skills acquired: clinical management of atopic dermatitis and chronic spontaneous urticaria, prescription of biologics and small molecules.
Clinical research: data collection, scientific writing.

MEDICO SPECIALIZZANDO / MD RESIDENT ALLERGOLOGIA E IMMUNOLOGIA CLINICA U.O. ALLERGOLOGIA E IMMUNOLOGIA IRCCS AUXOLOGICO SAN LUCA (PROF. F. CAPSONI) – UNIVERSITÀ DEGLI STUDI DI MILANO – 01/02/2022 – 31/07/2022

Servizi / ambulatori frequentati: ambulatorio di allergologia, ambulatorio immunologia clinico, day hospital immunologico.
Services / Clinics Attended: Allergy clinic, clinical immunology clinic, immunology day hospital.

MEDICO SPECIALIZZANDO / MD RESIDENT ALLERGOLOGIA E IMMUNOLOGIA CLINICA U.O.C. ALLERGOLOGIA OSPEDALE NIGUARDA (PROF.SSA E. A. PASTORELLO) – UNIVERSITÀ DEGLI STUDI DI MILANO – 01/01/2021 – 31/01/2022 – MILANO, ITALY

Servizi / ambulatori frequentati: ambulatorio di allergologia, ambulatorio di secondo livello per food-allergy, day hospital e Macroattività Ambulatoriale ad alta Complessità (MAC) per test allergologici ai farmaci (FANS, antibiotici, anestetici locali, generali e mezzi di contrasto).

Services / Clinics Attended: Allergy clinic, second-level clinic for food allergy, day hospital, and High Complexity Outpatient Macro-Activities (MAC) for allergological drug testing (NSAIDs, antibiotics, local and general anesthetics, and contrast agents).

INVESTIGATOR IN TRIAL CLINICI / INVESTIGATOR IN CLINICAL TRIALS – S.C. DERMAOTLOGIA / DERMATOLOGY UNIT IRCCS CA' GRANDA POLICLINICO DI MILANO – 01/08/2022 – Current – MILANO, ITALY

- Protocol CS45570: "A Phase II Study of RO07790121 in Moderate-to-Severe AD - Roche - PI Dr. Silvia Ferrucci
- Protocol M24-601: "A Study of Upadacitinib in Adult Subjects with Moderate-to-Severe Atopic Dermatitis in Inadequate Response to Dupilumab (SWITCH-UP) - AbbVie - PI Dr. Silvia Ferrucci
- Protocol SP2011MP301: "Clinical Evaluation of Metal Panel Allergens - Safety&Efficiency" - Smart Practice - PI Dr. Silvia Ferrucci
- Protocol DA_CeraVe: "Analisi dell'effetto sul ripristino dell'idratazione della barriera cutanea attraverso l'utilizzo della crema idratante CeraVe in regime di mantenimento in soggetti con dermatite atopica da lieve a moderata - SIDeMAaST - PI Prof. Angelo Valerio Marzano
- Protocol EFC16973: “Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)” – Sanofi – PI Dr. Silvia Ferrucci
- Protocol M22-000: “A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis (Flex-Up)” – AbbVie - PI Dr. Silvia Ferrucci
- Protocol M23-696: “A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up)” - AbbVie - PI Dr. Silvia Ferrucci
- Protocol 20210146: “A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-tosevere Atopic Dermatitis (AD) (ROCKETASCEND)” – Amgen - PI Dr. Silvia Ferrucci
- Protocol 20210145: “A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)” - Amgen - PI Dr. Silvia Ferrucci
- Protocol INCB18424-320: “A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis” – Incyte - PI Dr. Silvia Ferrucci
- Protocol INCB18424-326 TRuE-AD4: “A Phase 3B, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis” – Incyte - PI Dr. Silvia Ferrucci
- Protocol CLOU064A2304: “A global, multicenter, randomized, double-blind, doubledummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines” – Novartis - PI Dr. Silvia Ferrucci
- Protocol OBS18015: “A prospective observational study of adolescent patients with severe atopic dermatitis despite less extensive skin lesions (Eczema Area and Severity Index score < 16) receiving dupilumab (AD-BEASCUITS)” – Sanofi - PI Dr. Silvia Ferrucci
- EFC17561: “A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids.” - Sanofi - PI Dr. Silvia Ferrucci

MEDICO LIBERO PROFESSIONISTA / MEDICAL DOCTOR FREELANCE – TECO S.R.L. – 01/11/2020 – 25/01/2021 – FIORENZUOLA, ITALY

Diagnosi SARS-COV 2 (esecuzione tamponi nasofaringei)

SARS-COV-2 Diagnosis (nasopharyngeal swab testing)

ASSISTENTE ALLA FORMAZIONE PER LE IMPRESE / CORPORATE TRAINING ASSISTANT – SIRIO S.R.L. – 30/03/2020 – 30/11/2020 – BERGAMO, ITALY

Docente corsi primo soccorso e sicurezza sul lavoro
Instructor for First Aid and Workplace Safety Courses

EDUCATION AND TRAINING

19/05/2025 – 20/06/2025 Phoenix, United States
MEDICO OSSERVATORE Saguaro Dermatology

23/01/2025 – 25/01/2025 Phoenix, United States
PATCH TEST TRAINING COURSE Contact Dermatitis Institute

Website https://www.contactdermatitisinstitute.com

26/01/2021 – 26/01/2025 Milano, Italy
SPECIALIZZANDO IN ALLERGOLOGIA E IMMUNOLOGIA CLINICA / RESIDENT IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY Università degli Studi di Milano

26/03/2024 – CURRENT
ADVANCED CARDIOVASCULAR LIFE SUPPORT - ACLS Università degli Studi di Milano - American Heart Association

01/10/2013 – 30/07/2019 Milano, Italy
LAUREA MAGISTRALE IN MEDICINA E CHIRURGIA / MEDICAL SCHOOL Università degli Studi di Milano

Internato presso S.C. Dermatologia, IRCCS Policlinico di Milano, dal novembre 2016 al luglio 2019.
Internal at the Dermatology Unit, IRCCS Policlinico of Milan, from November 2016 to July 2019.

Thesis Follow-up ecografico dei pazienti affetti da idrosadenite suppurativa in terapia con Adalimuab

LANGUAGE SKILLS

Mother tongue(s): **ITALIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	B2	B2	B2	B2	B2
FRENCH	B1	B1	A2	A2	A2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

SKILLS

Microsoft Powerpoint | ECDL | Microsoft Office | Microsoft Excel | Microsoft Word

PUBLICATIONS

Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis

Avallone G, Bombelli A, Valtellini L, Tavoletti G, Galli B, Rossi M, Maurelli M, Girolomoni G, Gargiulo L, Narcisi A, di Vico F, Napolitano M, Lazzeri L, Calabrese L, Caccavale S, Balato A, Barei F, Calzari P, Foti C, Trave I, Cozzani E, Rongioletti F, Lenti S, Gurioli C, Nettis E, Caroppo F, Errichetti E, Bonzano L, Gori N, Peris K, Lembo S, Del Regno L, Esposito M, Fargnoli MC, Savoia P, Esposto E, Giuffrida R, Guarneri F, Patruno C, Pezzolo E, Stingeni L, Hansel K, Mastorino L, Ortoncelli M, Ribero S, Marzano AV, Ferrucci SM.Write here the description...

Clin Exp Dermatol. 2025 Jul 16:llaf302. doi: 10.1093/ced/llaf302

Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.

Avallone G, Bombelli A, Gargiulo L, Foti C, Trave I, Rossi M, Magnaterra E, Pigliacelli F, Malagoli P, Giacalone S, Portarapillo A, Patruno C, Schettini N, Bonzano L, Pezzolo E, Chello C, Gori N, Brunasso G, Veronese F, Ortoncelli M, Tolino E, Azzolini A, Bellinato F, Hansel K, Di Brizzi EV, Gurioli C, Esposito M, Giuffrida R, Barei F, Calzari P, Burroni AG, Gola M, Mariano M, Fargnoli MC, Napolitano M, Grieco T, Peris K, Savoia P, Ribero S, Girolomoni G, Stingeni L, Balato A, Costanzo A, Marzano AV, Narcisi A, Ferrucci SM.

Dermatol Ther (Heidelb). 2025 Oct 10.

Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study.

Barei F, Macchi S, Calzari P, Ribero S, Ortoncelli M, Foti C, Balato A, Di Brizzi EV, Peris K, Gori N, Ippoliti E, Gurioli C, Piraccini BM, Trave I, Cozzani E, Pezzolo E, Bonzano L, Errichetti E, Schettini N, Nettis E, Gola M, Milanesi N, Feliciani C, De Felici Del Giudice MB, Campanati A, Gioacchini H, Pisapia A, Avallone G, Micali G, Musumeci ML, Ortega R, Manzo Margiotta F, Romanelli M, Hansel K, Stingeni L, Patruno C, Esposito M, Fargnoli MC, De Berardinis A, Ferreli C, Calabrese L, Rubegni P, Lazzeri L, Grigolato L, Galli B, Rossi M, Maurelli M, Girolomoni G, Lauletta G, Napolitano M, Alfano A, Gargiulo L, Narcisi A, Marzano AV, Ferrucci SM. Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study. Clin Exp Dermatol. 2025 Jun 20:llaf275. doi: 10.1093/ced/llaf275. Epub ahead of print. PMID: 40578600.

2025
The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Caroppo ES, Casciola G, Hansel K, Guglielmo A, Ferrucci SM, Guarneri F, Lauriola MM, Napolitano M, Patruno C, Romita P, Schena D, Trave I, Bianchi L, Stingeni L; 2-HEMA Study Group. The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working? Contact Dermatitis. 2025 May 21. doi: 10.1111/cod.14800. Epub ahead of print. PMID: 40400120.

2025
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.

Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti MB, Caroppo F, Belloni Fortina A, Patruno C, Campanati A, Bianchelli T, D'Agostino GM, Nettis E, Pugliese F, di Vico F, Trave I, Cozzani E, Stingeni L, Hansel K, Dall'Olio M, Grigolato L, Coppola R, Panasiti V, Maurelli M, Girolomoni G, Ortoncelli M, Ribero S, Marzano AV, Ferrucci SM.

Barei F, Calzari P et al.

2025
Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study

Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti MB, Caroppo F, Belloni Fortina A, Patruno C, Campanati A, Bianchelli T, D'Agostino GM, Nettis E, Pugliese F, Picone V, Trave I, Cozzani E, Stingeni L, Hansel K, Dall'Olio M, Galli B, Coppola R, Panasiti V, Maurelli M, Girolomoni G, Ortoncelli M, Ribero S, Marzano AV, Ferrucci SM.

Barei F, Calzari P et al.

2025
Severe Allergic Contact Dermatitis to Hair Dye in a Patient With Atopic Dermatitis During Dupilumab Therapy.

Chiei Gallo A, Tavoletti G, Avallone G, Bono E, Barei F, Calzari P, Marzano AV, Ferrucci SM.

Successful treatment of prurigo nodularis with upadacitinib.

Avallone G, Bombelli A, Termini D, Chiei-Gallo A, Calzari P, Barei F, Marzano AV, Ferrucci SM.

Clin Exp Dermatol. 2025 Jun 25;50(7):1424-1426. doi: 10.1093/ced/llae329. PMID: 39140207.

2024

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Asero, R.; Calzari, P.; Vaienti, S.; Cugno, M. Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. *Pharmaceuticals* **2024**, *17*, 1499. https://doi.org/10.3390/ph17111499

Link https://doi.org/10.3390/ph17111499

2024

Severe chronic spontaneous urticaria responding and not responding to omalizumab: analysis of the prognostic value of known and novel in-vitro variables.

Asero R, Calzari P, Ferrucci S, Lorini M, Carbonelli V, Stella S, Consonni D, Cugno M. Severe chronic spontaneous urticaria responding and not responding to omalizumab: analysis of the prognostic value of known and novel in-vitro variables. Eur Ann Allergy Clin Immunol. 2024 Nov 15. doi: 10.23822/EurAnnACI.1764-1489.375. Epub ahead of print. PMID: 39545767.

Long-term efficacy and safety of dupilumab in adolescents with severe atopic dermatitis: a 3-year real-life study.

Chiei-Gallo A, Barei F, Calzari P, Pisapia A, Marzano AV, Ferrucci SM. Long-term efficacy and safety of dupilumab in adolescents with severe atopic dermatitis: a 3-year real-life study. Int J Dermatol. 2024 Oct 13. doi: 10.1111/ijd.17514. Epub ahead of print. PMID: 39397252.Write here the description...

2024

Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors

Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S, Zussino M, Marzano AV, Ferrucci S. Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat. 2024 Dec; 35(1):2404718. doi: 10.1080/09546634.2024.2404718. Epub 2024 Oct 13. PMID: 39396818.Write here the description...

2024

Three-Year Observational Study on the Long-Term Efficacy and Safety of Dupilumab in Elderly Patients with Severe Atopic Dermatitis

Chiei-Gallo A, Barei F, Calzari P, Pisapia A, Marzano AV, Ferrucci SM. Three-Year Observational Study on the Long-Term Efficacy and Safety of Dupilumab in Elderly Patients with Severe Atopic Dermatitis. Clin Exp Dermatol. 2024 Oct 10:llae420. doi: 10.1093/ced/llae420. Epub ahead of print. PMID: 39388584.

2024

Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience

Calzari P, Chiei Gallo A, Barei F, Bono E, Cugno M, Marzano AV, Ferrucci SM. Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience. J Clin Med. 2024 Sep 21;13(18): 5610. doi: 10.3390/jcm13185610. PMID: 39337097; PMCID: PMC11432798.

2024

Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centres

Tavoletti G, Chiei-Gallo A, Gargiulo L, Avallone G, Ibba L, Barei F, Calzari P, Narcisi A, Marzano AV, Ferrucci SM. Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centres. J Eur Acad Dermatol Venereol. 2024 Jun 28. doi: 10.1111/jdv.20202. Epub ahead of print. PMID: 38940608.

2024

Contact System Activation and Bradykinin Generation in Patients With Idiopathic Angioedema

Suffritti C, Calzari P, Depetri F, Griffini S, Grovetti E, Santacroce R, Margaglione M, Cugno M. Contact System Activation and Bradykinin Generation in Patients With Idiopathic Angioedema. J Investig Allergol Clin Immunol. 2024 Oct 23;34(5): 333-335. doi: 10.18176/jiaci.0996. Epub 2024 Feb 21. PMID: 38381073.

Link https://www.jiaci.org/summary/vol34-issue5-num2935

2024

Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients

Barei F, Zussino M, Tavecchio S, Angileri L, Rizzo A, Calzari P, Marzano AV, Ferrucci S. Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients. Pharmaceuticals (Basel). 2024 Jan 16;17(1):117. doi: 10.3390/ph17010117. PMID: 38256950; PMCID: PMC10821420.

Link https://doi.org/10.3390/ph17010117

2023

The role of imaging technologies in the diagnosis of hidradenitis suppurativa

Nazzaro G, Calzari P, Vaienti S, Passoni E, Marzano AV. The role of imaging technologies in the diagnosis of hidradenitis suppurativa. Clin Dermatol. 2023 Sep-Oct;41(5):611-621. doi: 10.1016/j.clindermatol.2023.08.023. Epub 2023 Aug 30. PMID: 37652192.

2023

Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature

Vaienti S, Calzari P, Nazzaro G. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature. Dermatol Ther (Heidelb). 2023 Oct;13(10): 2187-2215. doi: 10.1007/s13555-023-00993-1. Epub 2023 Aug 24. PMID: 37615838; PMCID: PMC10539275.

2023

Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?

Asero R, Ferrucci SM, Calzari P, Consonni D, Cugno M. Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? Int J Mol Sci. 2023 Apr 19;24(8):7491. doi: 10.3390/ijms24087491. PMID: 37108654; PMCID: PMC10139159.

2023

Uses of Polypodium leucotomos Extract in Oncodermatology

Calzari P, Vaienti S, Nazzaro G. Uses of *Polypodium leucotomos* Extract in Oncodermatology. J Clin Med. 2023 Jan 14;12(2):673. doi: 10.3390/jcm12020673. PMID: 36675602; PMCID: PMC9861608.

2021

Lymph Node Involvement in Axillary Hidradenitis Suppurativa: A Clinical, Ultrasonographic and Bacteriological Study Conducted during Radical Surgery

Vaienti S, Nazzaro G, Grancini A, Calzari P, Zaccaria G, Veraldi S, Vaienti L. Lymph Node Involvement in Axillary Hidradenitis Suppurativa: A Clinical, Ultrasonographic and Bacteriological Study Conducted during Radical Surgery. J Clin Med. 2021 Apr 1;10(7):1433. doi: 10.3390/jcm10071433. PMID: 33916058; PMCID: PMC8037287.

2021

Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients

Nazzaro G, Calzari P, Passoni E, Vaienti S, Moltrasio C, Barbareschi M, Muratori S, Veraldi S, Marzano AV. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients. Dermatol Ther. 2021 Jan;34(1):e14706. doi: 10.1111/dth.14706. Epub 2021 Jan 3. PMID: 33368976.

Ultrasonographic assessment of fibrosis in hidradenitis suppurativa fistulae helps in addressing treatment

Nazzaro G, Passoni E, Calzari P, Marzano AV. Ultrasonographic assessment of fibrosis in hidradenitis suppurativa fistulae helps in addressing treatment. Skin Res Technol. 2020 May;26(3):445-446. doi: 10.1111/srt.12805. Epub 2019 Nov 24. PMID: 31762109.

Link https://onlinelibrary.wiley.com/doi/10.1111/srt.12805

2019

Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions

Nazzaro G, Passoni E, Calzari P, Barbareschi M, Muratori S, Veraldi S, Marzano AV. Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions. Skin Res Technol. 2019 Nov;25(6):830-834. doi: 10.1111/srt.12729. Epub 2019 May 29. PMID: 31140660.

Link https://onlinelibrary.wiley.com/doi/10.1111/srt.12729